Fitch revises outlook amid leverage concerns
Fitch Ratings said on Thursday that it has changed the outlook on FMC Corporation to Negative from Stable, while leaving the company's Long-Term Issuer Default Rating (IDR) unchanged at 'BB+'. The firm also reaffirmed several other debt assessments for FMC: the senior unsecured rating at 'BB+' with a Recovery Rating of 'RR4', the Short-Term IDR and commercial paper at 'B', and the junior subordinated rating at 'BB-' with an 'RR6' recovery profile.
Why the outlook turned Negative
Fitch tied the outlook move to the risk that FMC's EBITDA leverage will exceed the agency's 4.5x downgrade threshold if the company cannot materially reduce debt through asset dispositions or commercial transactions. The rating action also reflects uncertainty related to FMC's review of strategic alternatives, which Fitch said includes the possibility of a sale of the company. The 'BB+' IDR itself reflects ongoing pressures from greater generic competition, which Fitch says has weighed on earnings and cash flow generation and is likely to keep leverage elevated over an extended period.
Projections for leverage and cash flow
Fitch's base case anticipates leverage rising above 4.5x in 2025 due to lower EBITDA and negative free cash flow after dividends, and remaining high through 2028. According to the agency, leverage begins to decline in 2026 as debt-reduction actions take effect, but operating weakness is expected to persist that year. Near-term contribution from FMC's growth portfolio is forecast to only partially offset the combined effects of generic competition and increased working capital requirements tied to competitor payment terms.
Fitch also expressed the view that FMC will be unable to achieve meaningful deleveraging unless it successfully implements licensing agreements for certain intellectual property assets or executes other significant commercial transactions to generate proceeds for debt reduction.
Product and regional pressures
The agency highlighted heightened generic penetration in Latin America as a material headwind for FMC's branded products Rynaxypyr and Cyazypyr, which together account for roughly 30% of the company's revenue. This increased generic activity has eroded pricing and volumes for those key products.
Company actions and mitigation factors
FMC has announced a manufacturing restructuring expected to lower operating costs by about $175 million annually and to improve its competitive position. The company is shifting emphasis toward data-protected products and new active ingredients that face less generic pressure. In addition, a dividend reduction will lower annual cash outlays by approximately $250 million starting in 2026. Fitch expects the smaller dividend burden to help FMC manage restructuring expenses and higher interest costs, resulting in roughly break-even free cash flow in 2026 with potential improvement thereafter.
Rating support
Despite the downgrade risk reflected in the Negative Outlook, Fitch noted supportive elements for the rating, including FMC's status as a major global crop protection company with a diversified product mix, broad geographic footprint and varied crop exposure.
This report focuses on Fitch's published assessment and the financial and operational items cited by the agency; it does not include additional forecasts or external commentary beyond those details.